Department of Medicine, Neuroscience Research Unit, Hôpital Saint-Luc (CRCHUM), Université de Montréal, Montreal, Quebec, Canada.
Clin Pharmacol Ther. 2012 Sep;92(3):321-31. doi: 10.1038/clpt.2012.112. Epub 2012 Aug 8.
Hyperammonemia leads to neurotoxic levels of brain ammonia and is a major factor involved in the pathogenesis of hepatic encephalopathy (HE). Ammonia-lowering treatments primarily involve two strategies: inhibiting ammonia production and/or increasing ammonia removal. Targeting the gut has been the primary focus for many years, with the goal of inhibiting the generation of ammonia. However, in the context of liver failure, extrahepatic organs containing ammonia metabolic pathways have become new potential ammonia-lowering targets. Skeletal muscle has the capacity to remove ammonia by producing glutamine through the enzyme glutamine synthetase (amidation of glutamate) and, given its large mass, has the potential to be an important ammonia-removing organ. On the other hand, glutamine can be deaminated to glutamate by phosphate-activated glutaminase, thus releasing ammonia (ammonia rebound). Therefore, new treatment strategies are being focused on stimulating the removal of both ammonia and glutamine.
高氨血症导致脑氨毒性水平升高,是肝性脑病 (HE) 发病机制的主要因素。降低血氨的治疗主要涉及两种策略:抑制氨的生成和/或增加氨的清除。多年来,靶向肠道一直是重点,目的是抑制氨的生成。然而,在肝功能衰竭的情况下,含有氨代谢途径的肝外器官已成为新的潜在降氨靶点。骨骼肌通过谷氨酰胺合成酶(谷氨酸酰胺化)产生谷氨酰胺来去除氨,并且由于其质量大,具有成为重要的氨去除器官的潜力。另一方面,谷氨酰胺可以被磷酸激活的谷氨酰胺酶脱氨生成谷氨酸,从而释放氨(氨反弹)。因此,新的治疗策略侧重于刺激氨和谷氨酰胺的清除。